Recurrent venous thromboembolism and vaginal estradiol in women with prior venous thromboembolism: A nested case-control study.
deep vein thrombosis
genitourinary syndrome
pulmonary embolism
recurrent venous thromboembolism
vaginal estradiol
venous thromboembolism
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
08 Aug 2024
08 Aug 2024
Historique:
revised:
18
07
2024
received:
07
04
2024
accepted:
21
07
2024
medline:
8
8
2024
pubmed:
8
8
2024
entrez:
8
8
2024
Statut:
aheadofprint
Résumé
Whether vaginal estradiol use is associated with an increased risk of recurrent venous thromboembolism (VTE) in women with prior VTE is unknown. We sought to evaluate the association between vaginal estradiol use and recurrent VTE in women with prior VTE. We performed a nationwide nested case-control study among 44 024 women aged ≥45 years who developed a first VTE without a history of vaginal estrogen use prior to VTE diagnosis. Cases with recurrent VTE were matched 1:2 on birth year with controls using incidence density sampling. Exposure to vaginal estradiol tablets was categorized into current use (0-2 months before index), prior use (2-24 months before index) and past use (more than 24 months prior to index). We identified 5066 cases and 10 127 age-matched controls. In fully adjusted analysis vaginal estrogen was not associated with recurrent VTE with a hazard ratio of 0.75, p = .07 for current use, 0.83, p = .13 for prior use, and 1.24, p = .06 for past use. Use of vaginal estradiol tablets in women with prior VTE was not associated with an increased rate of recurrent VTE. Our study indicates that vaginal estradiol therapy is unlikely to increase risk of recurrent VTE in women with prior VTE.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Canonico M, Plu‐Bureau G, Lowe GDO, Scarabin P‐Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta‐analysis. BMJ. 2008;336:1227‐1231.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728‐753.
Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215:704‐711.
Lethaby A, Ayeleke RO, Roberts H. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016:CD001500.
Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018;25:11‐20.
Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause. 2020;27:339‐360.
Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. Menopause. 2018;26:603‐610.
Vinogradova Y, Coupland C, Hippisley‐Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case–control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause. 2020;27:976‐992.
Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low‐dose vaginal estrogens. Menopause. 2019;27:361‐370.
Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient register: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449‐490.
Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription register. Scand J Public Health. 2011;39:38‐41.
Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39:22‐25.
Erlangsen A, Fedyszyn I. Danish nationwide registers for public health and health‐related research. Scand J Public Health. 2015;43:333‐339.
Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case–control and survival analysis methodologies for analysis of time‐dependent exposure. BMC Med Res Methodol. 2005;5:5.
Meaidi A, Goukasian I, Lidegaard O. Use of vaginal estrogen in Danish women: a nationwide cross‐sectional study. Acta Obstet Gynecol Scand. 2016;95:280‐284.
Meaidi M, Støvring H, Rostgaard K, et al. Pharmacoepidemiological methods for computing the duration of pharmacological prescriptions using secondary data sources. Eur J Clin Pharmacol. 2021;77:1805‐1814.
incidenceMatch. incidenceMatch—Risk set matching for nested case–control … in tagteam/heaven: data preparation routines for medical register data [Internet]. Accessed April 7, 2023. https://rdrr.io/github/tagteam/heaven/man/incidenceMatch.html
Wolkewitz M, Cooper BS, Palomar‐Martinez M, Olaechea‐Astigarraga P, Alvarez‐Lerma F, Schumacher M. Brief report: nested case–control studies in cohorts with competing events. Epidemiology. 2014;25:122‐125.
Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22:201‐210.
Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26:431‐453.
White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:1‐4.
Bell EJ, Lutsey PL, Basu S, et al. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med. 2016;129:339.e19‐339.e26.